Myocardial catecholamines in hypertrophic and dilated (congestive) cardiomyopathy: a biopsy study
C Kawai,
Y Yui,
T Hoshino,
S Sasayama,
and
A Matsumori
A high performance liquid chromatographic method was used to determine myocardial norepinephrine and epinephrine concentrations in 66 biopsy specimens obtained from the right or left ventricle during routine diagnostic cardiac catheterization of 45 patients with dilated (congestive) or hypertrophic cardiomyopathy, or with heart disease other than cardiomyopathy, such as acute perimyocarditis, postmyocarditis and constrictive pericarditis. The validity of catecholamine determination in a 2 to 6 mg biopsy specimen to assess overall ventricular myocardial catecholamines was demonstrated. Norepinephrine concentrations in the myocardium were inversely correlated with the grade of hypertrophy in patients with congestive cardiomyopathy or heart disease other than cardiomyopathy, but not in patients with hypertrophic cardiomyopathy. The fact that the myocardial norepinephrine concentration was always lower in the left than in the right ventricle of the same patient may be explained by the simple dilution of sympathetic nerve endings in the left ventricle. There were some cases of hypertrophic cardiomyopathy in which the concentration of myocardial norepinephrine was exceptionally high, although its mean value was not significantly higher than that in patients with other types of heart disease who served as a control group without cardiomyopathy. Some patients with dilated cardiomyopathy had lower levels of myocardial norepinephrine than would be expected for the degree of interstitial fibrosis and the severity of heart failure. The mean plasma norepinephrine and epinephrine levels were significantly elevated in patients with dilated cardiomyopathy.
This article has been cited by other articles:
|
|
|
|
 
S. D. Rosen, K. Murphy, A. P. Leff, V. Cunningham, R. J.S. Wise, L. Adams, A. J.S. Coats, and P. G. Camici
Is central nervous system processing altered in patients with heart failure?
Eur. Heart J.,
June 1, 2004;
25(11):
952 - 962.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. W. Lameris, S. de Zeeuw, D. J. Duncker, W. Tietge, G. Alberts, F. Boomsma, P. D. Verdouw, and A. H. van den Meiracker
Epinephrine in the Heart: Uptake and Release, but No Facilitation of Norepinephrine Release
Circulation,
August 13, 2002;
106(7):
860 - 865.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Schotten, K. Filzmaier, B. Borghardt, S. Kulka, F. Schoendube, C. Schumacher, and P. Hanrath
Changes of beta -adrenergic signaling in compensated human cardiac hypertrophy depend on the underlying disease
Am J Physiol Heart Circ Physiol,
June 1, 2000;
278(6):
H2076 - H2083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schafers, D. Dutka, C. G. Rhodes, A. A. Lammertsma, F. Hermansen, O. Schober, and P. G. Camici
Myocardial Presynaptic and Postsynaptic Autonomic Dysfunction in Hypertrophic Cardiomyopathy
Circ. Res.,
January 23, 1998;
82(1):
57 - 62.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
